Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q1 2022 Results - Earnings Call Transcript
06:12pm, Tuesday, 03'rd May 2022
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Nello Mainolfi - Founder and Chief Executive Officer Jared Gollob - Chief Medical O
Why Kymera Therapeutics Shares Are Falling Today
02:21pm, Tuesday, 03'rd May 2022
In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ: KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The coh
Why Kymera Therapeutics Stock Is Getting Hammered Today
01:09pm, Tuesday, 03'rd May 2022
The biotech upset investors today with disappointing news for its lead program.
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates
09:47am, Tuesday, 03'rd May 2022
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
08:00am, Tuesday, 19'th Apr 2022
Company to begin hosting quarterly calls to provide broad updates across pipeline Company to begin hosting quarterly calls to provide broad updates across pipeline
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
07:00am, Wednesday, 02'nd Mar 2022
WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates
11:35am, Thursday, 24'th Feb 2022
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the
BMEZ: Buy Low, Hold For The Distribution And Rebound
06:21am, Monday, 07'th Feb 2022
BMEZ: Buy Low, Hold For The Distribution And Rebound
Biotech: Interest ‘in vaccine stocks will probably wane,' strategist says
12:10pm, Wednesday, 22'nd Dec 2021
Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.
Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day
03:57pm, Tuesday, 30'th Nov 2021
Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue Estimates
09:57am, Wednesday, 10'th Nov 2021
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -64.71% and 0.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the
WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel s
Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences
08:00am, Monday, 01'st Nov 2021
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
Kymera: Targeting The Protein Degradation Space
07:27am, Friday, 22'nd Oct 2021
Kymera: Targeting The Protein Degradation Space
WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel s
